Opioids

The FDA’s Psychopharmacologic Drugs Advisory Committee recently reviewed and voted on whether to recommend lofexidine, a non-opioid drug, for the management of opioid withdrawal.

The authors of a recent study evaluated the 6-month effectiveness of a new program in treating individuals with substance use disorders. For details about the program, read more.

In a recent study, researchers sough to quantify the effects of opioid prescribing patterns following surgery on the risk of dependence, overdose, or abuse.

Extended-release naltrexone and sublingual buprenorphine-naloxone are pharmacologically distinct interventions to prevent opioid relapse.

After careful consideration, the FDA has requested that a particular opioid analgesic be removed from the market.

The FDA approved Vantrela ER tablets for the management of severe pain requiring daily opioid treatment which alternative treatment options have proven inadequate.

The FDA has approved a long-acting opioid painkiller designed to be difficult to crush, manipulate, and abuse.

A recent study evaluated gender differences in substance use, health, and social functioning in people receiving methadone treatment for opioid use disorder.

The FDA has approved a new opioid that features specific properties designed to deter, but not prevent, abuse.